medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2023-25-14-20medalphabet-3360Research ArticleСтатьиАнтикоагулянтная терапия у пациентов с фибрилляцией предсердий и хронической болезнью почек: за или противAnticoagulant therapy in patients with atrial fibrillation and chronic kidney disease: Arguments for or againsthttps://orcid.org/0000-0002-8633-7012КомароваА. Г.KomarovaA. G.

Комарова Анна Григорьевна, к.м.н., врач-кардиолог, зам. гл. врача по региональному сосудистому центру

Komarova Anna G., PhD Med, cardiologist, deputy chief physician for Regional Vascular Centre

bellis-06@mail.ruЛяховаН. Л.LyakhovaN. L.

Ляхова Наталия Леонидовна, к.м.н., врач-кардиолог, зав. кардиологическим отделением № 4

Lyakhova Natalia L., PhD Med, cardiologist, head of Cardiology Dept No. 4

https://orcid.org/0000-0001-7236-5699КованцевС. Д.CovantsevS. D.

Кованцев Сергей Дмитриевич, врач-хирург, н.с. 

Covantsev Serghei D., general surgeon, researcher

https://orcid.org/0009-0005-1994-871XНарышкинаЕ. А.NaryshkinaE. A.

Нарышкина Екатерина Александровна, врач-кардиолог

Naryshkina Ekaterina A., cardiologist

https://orcid.org/0000-0002-8121-6713СлепуховаД. В.SlepukhovaD. V.

Слепухова Диана Витальевна, врач-хирург, аспирант кафедры хирургии

Slepukhova Diana V., MD, general surgeon, PhD student at Dept of Surgery

ГБУЗ г. Москвы «Городская клиническая больница имени С.П. Боткина Департамента здравоохранения Москвы»РоссияBotkin HospitalRussian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy for Continuing Professional EducationRussian Federation202308112023025Кардиология. Неотложная медицина (3)1420Copyright © Комарова А.Г., Ляхова Н.Л., Кованцев С.Д., Нарышкина Е.А., Слепухова Д.В., 20232023Комарова А.Г., Ляхова Н.Л., Кованцев С.Д., Нарышкина Е.А., Слепухова Д.В.Komarova A.G., Lyakhova N.L., Covantsev S.D., Naryshkina E.A., Slepukhova D.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/3360

Фибрилляция предсердий, как и хроническая почечная недостаточность, являются распространенными состояниями среди населения, имеющие схожи факторы риска. Оба заболевания являются независимыми факторами риска развития тромбоэмболических осложнений. Существуют неопровержимые доказательства, подтверждающие преимущества антикоагулянтной терапии при фибрилляции предсердий в общей популяции, однако у пациентов с прогрессирующей хронической почечной недостаточностью возможность применения антикоагулянтов может быть ограничена. Ряд исследований показали противоречивые результаты, и данная тема представляет интерес для дальнейшего обсуждения и всестороннего анализа существующей проблемы.

Atrial fibrillation and chronic renal failure are common diseases in the population with similar risk factors. Both conditions are independent riskfactors for the development of thromboembolic complications. There is compelling evidence to support the benefits of anticoagulant therapy for atrial fibrillation in the general population, but in patients with advanced chronic renal failure, the use of anticoagulants may be limited. A number of studies have shown conflicting results, and this topic is of interest for further discussion and a comprehensive analysis of the existing data.

 

хроническая болезнь почекфибрилляция предсердийтромбоэмболияинсультchronic kidney diseaseatrial fibrillationthromboembolismstroke.ReferencesGo A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285 (18): 2370–5.Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285 (18): 2370–5.Ammirati A.L. Chronic Kidney Disease. Rev Assoc Med Bras. 2020; 66 Suppl 1 (Suppl 1): s03–9.Ammirati A.L. Chronic Kidney Disease. Rev Assoc Med Bras. 2020; 66 Suppl 1 (Suppl 1): s03–9.Olesen J. B., Lip G. Y.H., Kamper A.-L., Hommel K., Køber L., Lane D. A., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012; 367 (7): 625–35.Olesen J. B., Lip G. Y.H., Kamper A.-L., Hommel K., Køber L., Lane D. A., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012; 367 (7): 625–35.Wattanakit K., Cushman M., Stehman-Breen C., Heckbert S.R., Folsom A.R. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol. 2008; 19 (1): 135–40.Wattanakit K., Cushman M., Stehman-Breen C., Heckbert S.R., Folsom A.R. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol. 2008; 19 (1): 135–40.Kumar S., Lim E., Covic A., Verhamme P., Gale C.P., Camm A.J., et al. Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week. J Am Coll Cardiol. 2019; 74 (17): 2204–15.Kumar S., Lim E., Covic A., Verhamme P., Gale C.P., Camm A.J., et al. Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week. J Am Coll Cardiol. 2019; 74 (17): 2204–15.Abdelhafiz A.H., Myint M.P., Tayek J.A., Wheeldon N.M. Anemia, hypoalbuminemia, and renal impairment as predictors of bleeding complications in patients receiving anticoagulation therapy for nonvalvular atrial fibrillation: a secondary analysis. Clin Ther. 2009; 31 (7): 1534–9.Abdelhafiz A.H., Myint M.P., Tayek J.A., Wheeldon N.M. Anemia, hypoalbuminemia, and renal impairment as predictors of bleeding complications in patients receiving anticoagulation therapy for nonvalvular atrial fibrillation: a secondary analysis. Clin Ther. 2009; 31 (7): 1534–9.Sood M.M., Bota S.E., McArthur E., Kapral M.K., Tangri N., Knoll G., et al. The three-year incidence of major hemorrhage among older adults initiating chronic dialysis. Can J kidney Heal Dis. 2014; 1: 21.Sood M.M., Bota S.E., McArthur E., Kapral M.K., Tangri N., Knoll G., et al. The three-year incidence of major hemorrhage among older adults initiating chronic dialysis. Can J kidney Heal Dis. 2014; 1: 21.Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the Europe. Eur Heart J. 2021; 42 (5): 373–498.Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the Europe. Eur Heart J. 2021; 42 (5): 373–498.Granger C.B., Alexander J.H., McMurray J.J.V., Lopes R.D., Hylek E.M., Hanna M., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365 (11): 981–92.Granger C.B., Alexander J.H., McMurray J.J.V., Lopes R.D., Hylek E.M., Hanna M., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365 (11): 981–92.Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю., Голицын С.П., Голухова Е.З., Горев М. В., et al. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020.Arakelyan M.G., Bockeria L.A., Vasilyeva E. Yu., Golitsyn S.P., Golukhova E.Z., Gorev M.V., et al. Atrial fibrillation and flutter. Clinical Guidelines 2020.Gadde S., Kalluru R., Cherukuri S. P., Chikatimalla R., Dasaradhan T., Koneti J. Atrial Fibrillation in Chronic Kidney Disease: An Overview. Cureus. 2022; 14 (8): e27753.Gadde S., Kalluru R., Cherukuri S. P., Chikatimalla R., Dasaradhan T., Koneti J. Atrial Fibrillation in Chronic Kidney Disease: An Overview. Cureus. 2022; 14 (8): e27753.Soi V., Yee J. Sodium Homeostasis in Chronic Kidney Disease. Adv Chronic Kidney Dis. 2017; 24 (5): 325–31.Soi V., Yee J. Sodium Homeostasis in Chronic Kidney Disease. Adv Chronic Kidney Dis. 2017; 24 (5): 325–31.Qiu H., Ji C., Liu W., Wu Y., Lu Z., Lin Q., et al. Chronic Kidney Disease Increases Atrial Fibrillation Inducibility: Involvement of Inflammation, Atrial Fibrosis, and Connexins. Front Physiol. 2018; 9: 1726.Qiu H., Ji C., Liu W., Wu Y., Lu Z., Lin Q., et al. Chronic Kidney Disease Increases Atrial Fibrillation Inducibility: Involvement of Inflammation, Atrial Fibrosis, and Connexins. Front Physiol. 2018; 9: 1726.Nair G.M., Nery P.B., Redpath C.J., Birnie D.H. The Role Of Renin Angiotensin System In Atrial Fibrillation. J Atr Fibrillation. 2014; 6 (6): 972.Nair G.M., Nery P.B., Redpath C.J., Birnie D.H. The Role Of Renin Angiotensin System In Atrial Fibrillation. J Atr Fibrillation. 2014; 6 (6): 972.Reil J.-C., Hohl M., Selejan S., Lipp P., Drautz F., Kazakow A., et al. Aldosterone promotes atrial fibrillation. Eur Heart J [Internet]. 2012; 33 (16): 2098–108. https://doi.org/10.1093/eurheartj/ehr266Reil J.-C., Hohl M., Selejan S., Lipp P., Drautz F., Kazakow A., et al. Aldosterone promotes atrial fibrillation. Eur Heart J [Internet]. 2012; 33 (16): 2098–108. https://doi.org/10.1093/eurheartj/ehr266Chen Z.W., Hung C.S., Wu V.C., Lin Y.H. Primary Aldosteronism and Cerebrovascular Diseases. Endocrinol Metab (Seoul, Korea). 2018; 33 (4): 429–34.Chen Z.W., Hung C.S., Wu V.C., Lin Y.H. Primary Aldosteronism and Cerebrovascular Diseases. Endocrinol Metab (Seoul, Korea). 2018; 33 (4): 429–34.Nguyen V., Tu T.M., Mamauag M.J.B., Lai J., Saffari S.E., Aw T.C., et al. Primary Aldosteronism More Prevalent in Patients With Cardioembolic Stroke and Atrial Fibrillation. Front Endocrinol (Lausanne). 2022; 13: 869980.Nguyen V., Tu T.M., Mamauag M.J.B., Lai J., Saffari S.E., Aw T.C., et al. Primary Aldosteronism More Prevalent in Patients With Cardioembolic Stroke and Atrial Fibrillation. Front Endocrinol (Lausanne). 2022; 13: 869980.Rafaqat S., Rafaqat S., Khurshid H., Rafaqat S. Electrolyte’s imbalance role in atrial fibrillation: Pharmacological management. Int J Arrhythmia [Internet]. 2022; 23 (1): 15. https://doi.org/10.1186/s42444–022–00065-zRafaqat S., Rafaqat S., Khurshid H., Rafaqat S. Electrolyte’s imbalance role in atrial fibrillation: Pharmacological management. Int J Arrhythmia [Internet]. 2022; 23 (1): 15. https://doi.org/10.1186/s42444–022–00065-zAkhtar Z., Leung L. W., Kontogiannis C., Chung I., Bin Waleed K., Gallagher M.M. Arrhythmias in Chronic Kidney Disease. Eur Cardiol. 2022; 17: e05.Akhtar Z., Leung L. W., Kontogiannis C., Chung I., Bin Waleed K., Gallagher M.M. Arrhythmias in Chronic Kidney Disease. Eur Cardiol. 2022; 17: e05.Yamagami F., Tajiri K., Yumino D., Ieda M. Uremic Toxins and Atrial Fibrillation: Mechanisms and Therapeutic Implications. Toxins (Basel). 2019; 11 (10).Yamagami F., Tajiri K., Yumino D., Ieda M. Uremic Toxins and Atrial Fibrillation: Mechanisms and Therapeutic Implications. Toxins (Basel). 2019; 11 (10).Kaartinen K., Rautavaara J., Aitkoski A., Anttonen O., Ahvonen J., Vilpakka M., et al. Fluid overload is an independent predictor of atrial fibrillation in endstage renal dise.Kaartinen K., Rautavaara J., Aitkoski A., Anttonen O., Ahvonen J., Vilpakka M., et al. Fluid overload is an independent predictor of atrial fibrillation in endstage renal dise.Zhou X., Dudley S.C.J. Evidence for Inflammation as a Driver of Atrial Fibrillation. Front Cardiovasc Med. 2020; 7: 62.Zhou X., Dudley S.C.J. Evidence for Inflammation as a Driver of Atrial Fibrillation. Front Cardiovasc Med. 2020; 7: 62.Marott S. C.W., Nordestgaard B. G., Zacho J., Friberg J., Jensen G. B., Tybjærg-Hansen A., et al. Does Elevated C-Reactive Protein Increase Atrial Fibrillation Risk?: A Mendelian Randomization of 47,000 Individuals From the General Population. J Am Coll Cardiol [Internet]. 2010; 56 (10): 789–95.Marott S. C.W., Nordestgaard B. G., Zacho J., Friberg J., Jensen G. B., Tybjærg-Hansen A., et al. Does Elevated C-Reactive Protein Increase Atrial Fibrillation Risk?: A Mendelian Randomization of 47,000 Individuals From the General Population. J Am Coll Cardiol [Internet]. 2010; 56 (10): 789–95.Watanabe E., Arakawa T., Uchiyama T., Kodama I., Hishida H. High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol [Internet]. 2006; 108 (3): 346–53. https://doi.org/10.1016/j.ijcard.2005.05.021Watanabe E., Arakawa T., Uchiyama T., Kodama I., Hishida H. High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol [Internet]. 2006; 108 (3): 346–53. https://doi.org/10.1016/j.ijcard.2005.05.021Li J., Solus J., Chen Q., Rho Y.H., Milne G., Stein C.M., et al. Role of inflammation and oxidative stress in atrial fibrillation. Hear Rhythm [Internet]. 2010; 7 (4): 438–44. https://doi.org/10.1016/j.hrthm.2009.12.009Li J., Solus J., Chen Q., Rho Y.H., Milne G., Stein C.M., et al. Role of inflammation and oxidative stress in atrial fibrillation. Hear Rhythm [Internet]. 2010; 7 (4): 438–44. https://doi.org/10.1016/j.hrthm.2009.12.009Wu N., Xu B., Xiang Y., Wu L., Zhang Y., Ma X., et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: A meta-analysis. Int J Cardiol [Internet]. 2013; 169 (1): 62–72. https://doi.org/10.1016/j.ijcard.2013.08.078Wu N., Xu B., Xiang Y., Wu L., Zhang Y., Ma X., et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: A meta-analysis. Int J Cardiol [Internet]. 2013; 169 (1): 62–72. https://doi.org/10.1016/j.ijcard.2013.08.078Matsushita N., Ishida N., Ibi M., Saito M., Takahashi M., Taniguchi S., et al. IL-1β Plays an Important Role in Pressure Overload-Induced Atrial Fibrillation in Mice. Biol Pharm Bull. 2019; 42 (4): 543–6.Matsushita N., Ishida N., Ibi M., Saito M., Takahashi M., Taniguchi S., et al. IL-1β Plays an Important Role in Pressure Overload-Induced Atrial Fibrillation in Mice. Biol Pharm Bull. 2019; 42 (4): 543–6.da Silva R. M.F.L. Influence of Inflammation and Atherosclerosis in Atrial Fibrillation. Curr Atheroscler Rep [Internet]. 2017; 19 (1): 2. https://doi.org/10.1007/s11883–017–0639–0da Silva R. M.F.L. Influence of Inflammation and Atherosclerosis in Atrial Fibrillation. Curr Atheroscler Rep [Internet]. 2017; 19 (1): 2. https://doi.org/10.1007/s11883–017–0639–0Liuba I., Ahlmroth H., Jonasson L., Englund A., Jönsson A., Säfström K., et al. Source of inflammatory markers in patients with atrial fibrillation †. EP Eur [Internet]. 2008; 10 (7): 848–53. https://doi.org/10.1093/europace/eun111Liuba I., Ahlmroth H., Jonasson L., Englund A., Jönsson A., Säfström K., et al. Source of inflammatory markers in patients with atrial fibrillation †. EP Eur [Internet]. 2008; 10 (7): 848–53. https://doi.org/10.1093/europace/eun111Hu Y.-F., Chen Y.-J., Lin Y.-J., Chen S.-A. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol [Internet]. 2015; 12 (4): 230–43. https://doi.org/10.1038/nrcardio.2015.2Hu Y.-F., Chen Y.-J., Lin Y.-J., Chen S.-A. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol [Internet]. 2015; 12 (4): 230–43. https://doi.org/10.1038/nrcardio.2015.2Moretti R., Janjusevic M., Fluca A.L., Saro R., Gagno G., Pierri A., et al. Common Shared Pathogenic Aspects of Small Vessels in Heart and Brain Disease. Vol. 10, Biomedicines. 2022.Moretti R., Janjusevic M., Fluca A.L., Saro R., Gagno G., Pierri A., et al. Common Shared Pathogenic Aspects of Small Vessels in Heart and Brain Disease. Vol. 10, Biomedicines. 2022.Chen T.-H., Chu Y.-C., Ou S.-M., Tarng D.-C. Associations of atrial fibrillation with renal function decline in patients with chronic kidney disease. Heart [Internet]. 2022; 108 (6): 438 LP – 444. http://heart.bmj.com/content/108/6/438.abstractChen T.-H., Chu Y.-C., Ou S.-M., Tarng D.-C. Associations of atrial fibrillation with renal function decline in patients with chronic kidney disease. Heart [Internet]. 2022; 108 (6): 438 LP – 444. http://heart.bmj.com/content/108/6/438.abstractBeyer-Westendorf J., Kreutz R., Posch F., Ay C. The CHA2DS 2-VASc score strongly correlates with glomerular filtration rate and predicts renal function decline over time in elderly patients with atrial fibrillation and chronic kidney disease. Int J Cardiol [Internet]. 2018; 253: 71–7. https://doi.org/10.1016/j.ijcard.2017.10.110Beyer-Westendorf J., Kreutz R., Posch F., Ay C. The CHA2DS 2-VASc score strongly correlates with glomerular filtration rate and predicts renal function decline over time in elderly patients with atrial fibrillation and chronic kidney disease. Int J Cardiol [Internet]. 2018; 253: 71–7. https://doi.org/10.1016/j.ijcard.2017.10.110Migdady I., Russman A., Buletko A. B. Atrial Fibrillation and Ischemic Stroke: A Clinical Review. Semin Neurol. 2021; 41 (4): 348–64.Migdady I., Russman A., Buletko A. B. Atrial Fibrillation and Ischemic Stroke: A Clinical Review. Semin Neurol. 2021; 41 (4): 348–64.Gao X., Cai X., Yang Y., Zhou Y., Zhu W. Diagnostic Accuracy of the HAS-BLED Bleeding Score in VKA- or DOAC-Treated Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Vol. 8, Frontiers in cardiovascular medicine. Switzerland; 2021. p. 757087.Gao X., Cai X., Yang Y., Zhou Y., Zhu W. Diagnostic Accuracy of the HAS-BLED Bleeding Score in VKA- or DOAC-Treated Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Vol. 8, Frontiers in cardiovascular medicine. Switzerland; 2021. p. 757087.Noubiap J.J., Middeldorp M.E., Thomas G., Sanders P. CHA2DS2-VASc score is no longer enough-Authors’ reply. Vol. 24, Europace: European pacing, arrhythmias, and cardiac electrophysiology: Journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. England; 2022. p. 1195.Noubiap J.J., Middeldorp M.E., Thomas G., Sanders P. CHA2DS2-VASc score is no longer enough-Authors’ reply. Vol. 24, Europace: European pacing, arrhythmias, and cardiac electrophysiology: Journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. England; 2022. p. 1195.Wang M., Zeraatkar D., Obeda M., Lee M., Garcia C., Nguyen L., et al. Drugdrug interactions with warfarin: A systematic review and meta-analysis. Br J Clin Pharmacol. 2021; 87 (11): 4051–100.Wang M., Zeraatkar D., Obeda M., Lee M., Garcia C., Nguyen L., et al. Drugdrug interactions with warfarin: A systematic review and meta-analysis. Br J Clin Pharmacol. 2021; 87 (11): 4051–100.Марцевич С. Ю. Лукина Ю. В. Варфарин и его значение в эру новых оральных антикоагулянтов. Вопросы контроля эффективности и безопасности лечения. Рациональная фармакотерапия в кардиологии. 2017; 13 (5): 699–705.Martsevich S. Yu. Lukina Yu.V. Warfarin and its significance in the era of new oral anticoagulants. Issues of monitoring the effectiveness and safety of treatment. Rational Pharmacotherapy in Cardiology. 2017; 13 (5): 699–705.Merli G. J., Tzanis G. Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio? J Thromb Thrombolysis. 2009; 27 (3): 293–9.Merli G. J., Tzanis G. Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio? J Thromb Thrombolysis. 2009; 27 (3): 293–9.Новикова Т.Н. Особенности антикоагулянтной терапии при фибрилляции предсердий в сочетании с нарушением функции почек. Кардиология. 2021; 61 (10): 81–88. https://doi.org/10.18087/cardio.2021.10.n1767Novikova T.N. Features of anticoagulant therapy for atrial fibrillation in combination with impaired renal function. Cardiology. 2021; 61 (10): 81–88. https://doi.org/10.18087/cardio.2021.10.n1767Brodsky S. V., Satoskar A., Hemminger J., Rovin B., Hebert L., Ryan M. S., et al. Anticoagulant-Related Nephropathy in Kidney Biopsy: A Single-Center Report of 41 Cases. Kidney Med. 2019; 1 (2): 51–6.Brodsky S. V., Satoskar A., Hemminger J., Rovin B., Hebert L., Ryan M. S., et al. Anticoagulant-Related Nephropathy in Kidney Biopsy: A Single-Center Report of 41 Cases. Kidney Med. 2019; 1 (2): 51–6.Brodsky S., Eikelboom J., Hebert L. A. Anticoagulant-Related Nephropathy. J Am Soc Nephrol. 2018; 29 (12): 2787–93.Brodsky S., Eikelboom J., Hebert L. A. Anticoagulant-Related Nephropathy. J Am Soc Nephrol. 2018; 29 (12): 2787–93.Ruff C.T., Giugliano R.P., Braunwald E., Hoffman E.B., Deenadayalu N., Ezekowitz M.D., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet (London, England). 2014; 383 (9921): 955–62.Ruff C.T., Giugliano R.P., Braunwald E., Hoffman E.B., Deenadayalu N., Ezekowitz M.D., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet (London, England). 2014; 383 (9921): 955–62.Lip G.Y.H., Keshishian A., Li X., Hamilton M., Masseria C., Gupta K., et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2018; 49 (12): 2933–44.Lip G.Y.H., Keshishian A., Li X., Hamilton M., Masseria C., Gupta K., et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke. 2018; 49 (12): 2933–44.Vaitsiakhovich T., Coleman C.I., Kleinjung F., Vardar B., Schaefer B. Worsening of kidney function in patients with atrial fibrillation and chronic kidney disease: Evidence from the real-world CALLIPER study. Curr Med Res Opin [Internet]. 2022;38 (6): 937–45. https://doi.org/10.1080/03007995.2022.2061705Vaitsiakhovich T., Coleman C.I., Kleinjung F., Vardar B., Schaefer B. Worsening of kidney function in patients with atrial fibrillation and chronic kidney disease: Evidence from the real-world CALLIPER study. Curr Med Res Opin [Internet]. 2022;38 (6): 937–45. https://doi.org/10.1080/03007995.2022.2061705Nutescu E., Chuatrisorn I., Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: An update. J Thromb Thrombolysis [Internet]. 2011; 31 (3): 326–43. https://doi.org/10.1007/s11239–011–0561–1Nutescu E., Chuatrisorn I., Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: An update. J Thromb Thrombolysis [Internet]. 2011; 31 (3): 326–43. https://doi.org/10.1007/s11239–011–0561–1Kumar S., de Lusignan S., McGovern A., Correa A., Hriskova M., Gatenby P., et al. Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: A population based study from UK primary care. BMJ. 2018; 360: k342.Kumar S., de Lusignan S., McGovern A., Correa A., Hriskova M., Gatenby P., et al. Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: A population based study from UK primary care. BMJ. 2018; 360: k342.Hart R.G., Pearce L.A., Asinger R.W., Herzog C.A. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011; 6 (11): 2599–604.Hart R.G., Pearce L.A., Asinger R.W., Herzog C.A. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011; 6 (11): 2599–604.Limdi N.A., Beasley T.M., Baird M.F., Goldstein J.A., McGwin G., Arnett D.K., et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol. 2009; 20 (4): 912–21.Limdi N.A., Beasley T.M., Baird M.F., Goldstein J.A., McGwin G., Arnett D.K., et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol. 2009; 20 (4): 912–21.Yang F., Hellyer J. A., Than C., Ullal A. J., Kaiser D. W., Heidenreich P. A., et al. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart. 2017; 103 (11): 818–26.Yang F., Hellyer J. A., Than C., Ullal A. J., Kaiser D. W., Heidenreich P. A., et al. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart. 2017; 103 (11): 818–26.Malhotra K., Ishfaq M.F., Goyal N., Katsanos A.H., Parissis J., Alexandrov A.W., et al. Oral anticoagulation in patients with chronic kidney disease: A systematic review and meta-analysis. Neurology. 2019; 92 (21): e2421–31.Malhotra K., Ishfaq M.F., Goyal N., Katsanos A.H., Parissis J., Alexandrov A.W., et al. Oral anticoagulation in patients with chronic kidney disease: A systematic review and meta-analysis. Neurology. 2019; 92 (21): e2421–31.Turakhia M.P., Blankestijn P.J., Carrero J.-J., Clase C.M., Deo R., Herzog C.A., et al. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J[Internet]. 2018; 39 (24): 2314–25. https://doi.org/10.1093/eurheartj/ehy060Turakhia M.P., Blankestijn P.J., Carrero J.-J., Clase C.M., Deo R., Herzog C.A., et al. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J[Internet]. 2018; 39 (24): 2314–25. https://doi.org/10.1093/eurheartj/ehy060Tan J., Liu S., Segal J.B., Alexander G.C., McAdams-DeMarco M. Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: A systematic review and meta-analysis. BMC Nephrol. 2016; 17 (1): 157.Tan J., Liu S., Segal J.B., Alexander G.C., McAdams-DeMarco M. Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: A systematic review and meta-analysis. BMC Nephrol. 2016; 17 (1): 157.Carrero J.J., Evans M., Szummer K., Spaak J., Lindhagen L., Edfors R., et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA. 2014; 311 (9): 919–28.Carrero J.J., Evans M., Szummer K., Spaak J., Lindhagen L., Edfors R., et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA. 2014; 311 (9): 919–28.Chan K.E., Edelman E.R., Wenger J.B., Thadhani R.I., Maddux F.W. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015; 131 (11): 972–9.Chan K.E., Edelman E.R., Wenger J.B., Thadhani R.I., Maddux F.W. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015; 131 (11): 972–9.Heidbuchel H., Verhamme P., Alings M., Antz M., Diener H.-C., Hacke W., et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J. 2017; 38 (27): 2137–49.Heidbuchel H., Verhamme P., Alings M., Antz M., Diener H.-C., Hacke W., et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J. 2017; 38 (27): 2137–49.Di Lullo L., Magnocavallo M., Vetta G., Lavalle C., Barbera V., Ronco C. et al. [Atrial fibrillation, oral anticoagulation and nephroprotection: caution or bravery?]. G Ital Nefrol. 2022; 39 (2): 2022. Vol 2.Di Lullo L., Magnocavallo M., Vetta G., Lavalle C., Barbera V., Ronco C. et al. [Atrial fibrillation, oral anticoagulation and nephroprotection: caution or bravery?]. G Ital Nefrol. 2022; 39 (2): 2022. Vol 2.Yao X., Tangri N., Gersh B. J., Sangaralingham L. R., Shah N. D., Nath K. A., Noseworthy P. A. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017; 70 (21): 2621–2632. DOI: 10.1016/j.jacc.2017.09.1087.Yao X., Tangri N., Gersh B. J., Sangaralingham L. R., Shah N. D., Nath K. A., Noseworthy P. A. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017; 70 (21): 2621–2632. DOI: 10.1016/j.jacc.2017.09.1087.Reinecke H., Engelbertz C., Bauersachs R., Breithardt G., Echterhoff H.H., Gerß J., et al. A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study. Circulation. 2023; 24; 147 (4): 296–309. DOI: 10.1161/circulationaha.122.062779.Reinecke H., Engelbertz C., Bauersachs R., Breithardt G., Echterhoff H.H., Gerß J., et al. A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study. Circulation. 2023; 24; 147 (4): 296–309. DOI: 10.1161/circulationaha.122.062779.Kuno T., Takagi H., Ando T., Sugiyama T., Miyashita S., Valentin N. et al. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis. J Am Coll Cardiol. 2020; 28; 75 (3): 273–285. DOI: 10.1016/j.jacc.2019.10.059.Kuno T., Takagi H., Ando T., Sugiyama T., Miyashita S., Valentin N. et al. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis. J Am Coll Cardiol. 2020; 28; 75 (3): 273–285. DOI: 10.1016/j.jacc.2019.10.059.Fatima H, Nwankwo I, Anam M, Maharjan S, Amjad Z, Abaza A, Vasavada AM, Sadhu A, Valencia C, Khan S. Safety and Efficacy of Apixaban vs Warfarin in Patients With Stage 4 and 5 Chronic Kidney Disease: A Systematic Review. Cureus. 2022; 12; 14 (10): e30230. DOI: 10.7759/cureus.30230.Fatima H, Nwankwo I, Anam M, Maharjan S, Amjad Z, Abaza A, Vasavada AM, Sadhu A, Valencia C, Khan S. Safety and Efficacy of Apixaban vs Warfarin in Patients With Stage 4 and 5 Chronic Kidney Disease: A Systematic Review. Cureus. 2022; 12; 14 (10): e30230. DOI: 10.7759/cureus.30230.

The authors declare that there are no conflicts of interest present.